Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07820579) titled 'Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sara Elva Espinosa Padilla, MD

Condition: Ataxia-Telangiectasia (A-T) Ataxia-Telangiectasia

Intervention: Drug: Rapamune (sirolimus/rapamycin)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 11, 2024

Target Sample Size: 6

Countries of Recruitment: Mexico

To know more, visit https://clinicaltrials.gov/study/NCT07820...